The Disturbing Truth About New Medicines: Are They Really Better? (Pharmaceutical Chemistry)

🤑 Are newly approved drugs indeed therapeutically superior to already existing medicines? Does their pricing reflect their benefit? Are drugs with breakthrough designations and accelerated approvals actually more impactful than normal therapeutics? Watch this video to learn about these elements and more!

Please drop a like and comment to support the video's visibility, activate notifications and subscribe to the channel so you do not miss future videos!

  / totalsynthesis  
🚀 Thanks to all channel supporters!!!
  / totalsynthesis_official  
👉 Follow me on Instagram to follow updates on other random chemistry research and interesting news!
https://total-synthesis.com
https://total-synthesis.com/new-drugs...

00:00 Expensive, useless drugs, bankruptcy and chemistry
00:49 Rising healthcare and drug costs
01:58 "Me-too drugs" vs. therapeutically high-value drugs
02:41 Study #1: Are new drugs better? First versus supplementary indications
05:48 Study #2: Are accelerated drugs more valuable? Breakthroughs, fast track, priority review and accelerated approvals
07:43 Study #3: Are low benefit drugs cheaper than high benefit medicines?
08:44 "Useless" drug #1: Avastin in metastatic breast cancer (overall survival, progression free survival)
12:02 "Useless" drug #2: Rucaparib in ovarian cancer
13:37 Chemistry A: Large-scale process route (nitration, Leimgruber-Batcho)
15:04 Chemistry B: Streamlined organic synthesis (Heck, imino-Stetter Umpolung)
16:52 THANK YOU for your support!

Disclaimer - This channel does not provide medical advice!
No information on this channel is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of information on Youtube.

Key sources:
- Study #1: Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study: BMJ 2023, 382, e074166
- Study #2: Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study: BMJ 2020, 371, m3434
- Study #3: Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis: Lancet Oncology 2020, 21, 664
- The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab): Saudi Pharm J 2012, 20, 381
- Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO: Eur J Cancer 2011, 47, 2387
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer: N Engl J Med 2007, 357, 2666
- Multikilogram Scale-Up of a Reductive Alkylation Route to a Novel PARP Inhibitor: OPRD 2012, 16, 1897
- Total Synthesis of Rucaparib: JOC 2022, 87, 4813

Some recommended books on organic synthesis:
- Clayden, Greeves, Warren; Organic Chemistry (basic organic chemistry knowledge)
- Wyatt, Warren; Organic Synthesis: The Disconnection Approach (excellent introduction to retrosynthesis)
- Kurti, Czako; Strategic Applications of Named Reactions in Organic Synthesis (extensive toolkit of functional group reactions and applications thereof with common conditions)
- Nicolaou; Classics in Total Synthesis 1-3 (the ultimate total synthesis trilogy)
- Nicolaou; Molecules That Changed the World (the world's most important molecules and their impact on everyday life)
- Carreira, Kvaerno; Classics in Stereoselective Synthesis (compilation of the groundbreaking methods of stereoselective synthesis and application to synthesis of stereochemically complex structures)